某院血流感染大肠埃希菌临床特征及耐药性分析

doi:10.3760/cma.j.issn.1007-1245.2024.19.020

国际医药卫生导报 ›› 2024, Vol. 30 ›› Issue (19): 3267-3271.DOI: 10.3760/cma.j.issn.1007-1245.2024.19.020

某院血流感染大肠埃希菌临床特征及耐药性分析

刘灿华^1,2 蔡栋昊^1,2 李冉^1,2 苏歆^1,2 谭俊青^1,2

¹广东省第二中医院检验科，广州　510095；²广东省中医药研究开发重点实验室，广州　510095

收稿日期:2024-06-12 出版日期:2024-10-01 发布日期:2024-10-17
通讯作者: 谭俊青，Email：727033779@qq.com
基金资助:
广东省医学科学研究基金（B2023187）

Clinical features and drug resistance of Escherichia coli bloodstream infection at some hospital

Liu Canhua^1,2, Cai Donghao^1,2, Li Ran^1,2, Su Xin^1,2, Tan Junqing^1,2

¹Department of Clinical Laboratory, Guangdong Provincial Second Hospital of Traditional Chinese Medicine, Guangzhou 510095, China; ²Guangdong Provincial Key Laboratory of Research and Development in Traditional Chinese Medicine, Guangzhou 510095, China

Received:2024-06-12 Online:2024-10-01 Published:2024-10-17
Contact: Tan Junqing, Email: 727033779@qq.com
Supported by:
Research Fund for Medical Science in Guangdong (B2023187)

摘要/Abstract

摘要：

目的　分析广东省第二中医院221例大肠埃希菌血流感染患者的临床特征和耐药情况，为临床针对其感染合理使用抗菌药物和院感防控提供参考。方法　收集广东省第二中医院2021年1月至2023年12月血培养阳性菌株数据，筛选出221例非重复大肠埃希菌血流感染患者的临床信息及药敏结果，其中男95例（42.99%），女126例（57.01%），年龄26～97岁。根据是否产超广谱β-内酰胺酶（extended spectrum beta-lactamase，ESBLs）分为产ESBLs组（105例）和非产ESBLs组（116例）。采用χ²检验比较两组大肠埃希菌耐药率。结果　2021年1月至2023年12月，院内血培养阳性552例，其中大肠埃希菌血流感染患者221例。患者主要来自针康科（55例）和肿瘤科（31例）。产ESBLs大肠埃希菌共105株，占总数的47.51%。大肠埃希菌对左氧氟沙星（54.30%）、复方新诺明（50.68%）、头孢曲松（53.39%）和头孢呋辛（53.85%）的耐药率较高，但对阿米卡星（3.62%）和亚胺培南（5.43%）、厄他培南（5.43%）2种碳青霉烯类药物具有较高的敏感性。产ESBLs大肠埃希菌对亚胺培南、厄他培南、头孢他啶、头孢吡肟、头孢曲松、头孢呋辛和左氧氟沙星的耐药率比非产ESBLs大肠埃希菌的高（均P<0.05）。结论　广东省第二中医院大肠埃希菌血流感染主要分布在针康科和肿瘤科。大部分菌株产ESBLs，对多种常见抗生素耐药，但是对碳青霉烯类药物的敏感性较高，临床应合理选择抗菌药物，减少耐药菌的产生。

关键词:

血流感染, 大肠埃希菌, 临床特征, 耐药分析

Abstract:

Objective　To analyze the clinical features and drug resistance of 221 patients with Escherichia coli bloodstream infection at Guangdong Provincial Second Hospital of Traditional Chinese Medicine, and to provide references for the rational use of antimicrobial drugs and the prevention and control of hospital infection in clinical practice. Methods　The data of positive blood culture strains at Guangdong Provincial Second Hospital of Traditional Chinese Medicine from January 2021 to December 2023 were collected. The clinical information and drug sensitivity results of 221 patients with non-duplicative Escherichia coli bloodstream infection were screened, including 95 males (42.99%) and 126 females (57.01%); they were 26-97 years old. According to the production of extended spectyum beta-lactamase (ESBLs), they were divided into an ESBLs group (105 cases) and a non-ESBLs group (116 cases). The resistance rates were compared between the two groups by χ² test. Results　From January 2021 to December 2023, there were 552 cases of positive blood culture in the hospital, including 221 patients with Escherichia coli bloodstream infection. The patients were mainly from the departments of acupuncture (55 cases) and oncology (31 cases). There were 105 ESBLs-producing Escherichia coli strains, accounting for 47.51% of the total strains. Escherichia coli had high resistance rates to levofloxacin (54.30%), cotrimoxazole (50.68%), ceftriaxone (53.39%), and cefuroxime (53.85%), but had high sensitivity to amikacin (3.62%), carbapenems (5.43%), and ertapenem (5.43%). ESBLs-producing Escherichia coli had higher resistance rates to imipenem, ertapenem, ceftazidime, cefepime, ceftriaxone, cefuroxime, and levofloxacin than non-ESBL-producing Escherichia coli (all P<0.05). Conclusions　Escherichia coli bloodstream infection is mainly distributed in the departments of acupuncture and oncology. Most strains produce ESBLs and are resistant to many common antibiotics, but they are highly sensitive to carbapenems, so antimicrobial drugs should be reasonably selected in clinical practice to reduce the generation of drug-resistant bacteria.

Key words:

Bloodstream infection, Escherichia coli, Clinical features, Antimicrobial resistance analysis

刘灿华蔡栋昊李冉苏歆谭俊青.

某院血流感染大肠埃希菌临床特征及耐药性分析 [J]. 国际医药卫生导报, 2024, 30(19): 3267-3271.

Liu Canhua, Cai Donghao, Li Ran, Su Xin, Tan Junqing.

Clinical features and drug resistance of Escherichia coli bloodstream infection at some hospital [J]. International Medicine and Health Guidance News, 2024, 30(19): 3267-3271.

参考文献

[1] 陆雨晴. 鲍曼不动杆菌血流感染的流行病学及治疗进展[J]. 检验医学与临床, 2022, 19(10): 1427-1430. DOI: 10.3969/j.issn.1672-9455.2022.10.036.
[2] Kern WV, Rieg S. Burden of bacterial bloodstream infection-a brief update on epidemiology and significance of multidrug-resistant pathogens [J]. Clin Microbiol Infect, 2020, 26(2): 151-157. DOI: 10.1016/j.cmi.2019.10.031.
[3] Mogasale V, Ramani E, Mogasale VV, et al. What proportion of Salmonella Typhi cases are detected by blood culture? A systematic literature review [J]. Ann Clin Microbiol Antimicrob, 2016, 15(1): 32. DOI: 10.1186/s12941-016-0147-z.
[4] 陈凯妮,庞彩莲,吴品,等. 血培养病原菌报阳时间、菌群分布及耐药性分析[J]. 河南医学研究,2021,30(32):6097-6100. DOI:10.3969/j.issn.1004-437X.2021.32.045.
[5] 陈倩倩,宋缘缘,唐洪影,等. 2015-2018年血流感染病原菌菌群分布及耐药性分析[J]. 天津医科大学学报,2020,26(3):271-275.
[6] Ghafourian S, Sadeghifard N, Soheili S, et al. Extended spectrum beta-lactamases: definition, classification and epidemiology [J]. Curr Issues Mol Biol, 2015, 17: 11-21.
[7] Naushad VA, Purayil NK, Wilson GJ, et al. Epidemiology of urinary tract infection in adults caused by extended-spectrum beta-lactamase (ESBL)-producing Enterobacteriaceae - a case-control study from Qatar [J]. IJID Reg, 2022, 3: 278-286. DOI: 10.1016/j.ijregi.2022.05.001.
[8] 尚红,王毓三,申子瑜,等.全国临床检验操作流程[M].4版.北京:人民卫生出版社,2015.
[9] Paramita RI, Nelwan EJ, Fadilah F, et al. Genome-based characterization of Escherichia coli causing bloodstream infection through next-generation sequencing [J]. PLoS One, 2020, 15(12): e0244358. DOI: 10.1371/journal.pone.0244358.
[10] Hung WT, Cheng MF, Tseng FC, et al. Bloodstream infection with extended-spectrum beta-lactamase-producing Escherichia coli: the role of virulence genes [J]. J Microbiol Immunol Infect, 2019, 52(6): 947-955. DOI: 10.1016/j.jmii.2019.03.005.
[11] 朱金玉,牛桂林,李燕,等. 某医院血标本分离病原菌分布及耐药性分析[J]. 中国消毒学杂志,2023,40(1):51-53,57. DOI:10.11726/j.issn.1001-7658.2023.01.017.
[12] 宋婵婵,李艳红,樊俊. 108例大肠埃希菌血流感染临床分布特点及药敏分析[J]. 社区医学杂志,2023,21(15):806-809,816. DOI:10.19790/j.cnki.JCM.2023.15.09.
[13] 段纯,全斌,王妮,等. 老年大肠埃希菌血流感染的临床特征及耐药特点(附94例分析)[J]. 山东医药,2022,62(24):56-59. DOI:10.3969/j.issn.1002-266X.2022.24.014.
[14] 徐砚志,张亚南,刘丹,等. 血流感染产超广谱β-内酰胺酶大肠埃希菌的耐药性及危险因素分析[J]. 西北药学杂志,2023,38(5):214-219. DOI:10.3969/j.issn.1004-2407. 2023.05.038.
[15] Nakai H, Hagihara M, Kato H, et al. Prevalence and risk factors of infections caused by extended-spectrum β-lactamase (ESBL)-producing Enterobacteriaceae [J]. J Infect Chemother, 2016, 22(5): 319-326. DOI: 10.1016/j.jiac.2016.02.004.
[16] 郝娜,赵路,崔海伶,等. 血培养阳性报警时间联合降钙素原、中性粒细胞/淋巴细胞比值对大肠埃希菌血流感染患者死亡风险的预测价值[J]. 现代生物医学进展,2023,23(6):1055-1059. DOI:10.13241/j.cnki.pmb.2023.06.011.
[17] 邹小红,凌利芬,刘小晴,等. PCT、hs-CRP、D-D在评估血流感染严重程度及预后不良中的应用价值[J]. 检验医学与临床,2024,21(8):1149-1152,1156. DOI:10.3969/j.issn. 1672-9455.2024.08.026.
[18] 史树海,程景丽,戴缤,等. 老年患者大肠埃希菌血流感染的早期临床识别及预后不良分析[J]. 中国中西医结合急救杂志,2023,30(1):13-17. DOI:10.3969/j.issn.1008-9691. 2023.01.003.
[19] 吴益佳,李丽波,詹今越. 2017-2022年丽水市某三级医院血培养大肠埃希菌的耐药性分析[J]. 现代实用医学,2023,35(6):756-758. DOI:10.3969/j.issn.1671-0800. 2023.06.015.
[20] 何家花,汪阔,余成强. 血流感染产超广谱β-内酰胺酶大肠埃希菌的药敏结果及感染危险因素分析[J]. 现代检验医学杂志,2021,36(1):128-131. DOI:10.3969/j.issn.1671-7414.2021.01.032.
[21] Karaiskos I, Giamarellou H. Carbapenem-sparing strategies for ESBL producers: when and how [J]. Antibiotics (Basel), 2020, 9(2): 61. DOI: 10.3390/antibiotics9020061.
[22] Husna A, Rahman MM, Badruzzaman ATM, et al. Extended-spectrum β-lactamases (ESBL): challenges and opportunities [J]. Biomedicines, 2023, 11(11): 2937. DOI: 10.3390/biomedicines11112937.
[23] 李惠,包洋,黄纯兰. 血液科血流感染肺炎克雷伯菌和大肠埃希菌的耐药性及危险因素分析[J]. 安徽医药,2023,27(3):562-567. DOI: 10.3969/j.issn.1009-6469.2023.03.031.

某院血流感染大肠埃希菌临床特征及耐药性分析

Clinical features and drug resistance of Escherichia coli bloodstream infection at some hospital

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 13

编辑推荐

Metrics

[1]	王海峰吴照锋侯中玉李亮. 葡萄球菌相关PS患者临床特征及预后分析 [J]. 国际医药卫生导报, 2024, 30(5): 834-838.
[2]	刘允邵长生宋远征刘志杨锡明. 初始样本转移技术在老年骨折患者血培养采血中的应用效果分析 [J]. 国际医药卫生导报, 2024, 30(3): 493-498.
[3]	谢益潮张少霞刘伟婷刘小燕王丹彤. 2014—2023年某院精神科患者临床特征及发展趋势分析 [J]. 国际医药卫生导报, 2024, 30(18): 3126-3132.
[4]	李恒蒋士杰连鹏张晖. 不同肠系膜上动脉缺血性疾病60例分析 [J]. 国际医药卫生导报, 2024, 30(17): 2941-2945.
[5]	傅红梅俞朝贤李春燕谭毅刚岑滢李翠萍刘志辉. 肝移植术后肺结核患者的临床特点及诊疗分析 [J]. 国际医药卫生导报, 2024, 30(14): 2366-2370.
[6]	陈先平张立胜洪岩. 难治性肺炎支原体肺炎患儿临床特征及与TLR4炎症小体关联性强度 [J]. 国际医药卫生导报, 2024, 30(10): 1620-1625.
[7]	张云涛陈丽君. 胎盘后血肿和绒毛膜下血肿的临床特征及妊娠结局比较 [J]. 国际医药卫生导报, 2024, 30(1): 125-129.
[8]	潘聪付四毛杨祝玲. 儿童克罗恩病10例生长发育状况及临床特征分析 [J]. 国际医药卫生导报, 2023, 29(8): 1111-1116.
[9]	王夙昕邸玥莹邹慧青陈旭张勇翔张玲. 厦门地区医院感染大肠埃希菌及肺炎克雷伯菌产KPC的调查研究 [J]. 国际医药卫生导报, 2023, 29(11): 1514-1518.
[10]	高兰王婷婷崔付新张清清王相立. 单双相抑郁患者的临床特征及药物联合心理疗法的效果分析 [J]. 国际医药卫生导报, 2023, 29(10): 1430-1434.
[11]	唐学良张晖凌明强. 肝硬化食管静脉曲张破裂出血的临床特点与危险因素分析[J]. 国际医药卫生导报, 2022, 28(19): 2753-2757.
[12]	王娜　贾兴芳　储琳琳　郝佳慧　刘成霞. 人结直肠锯齿状腺癌的研究现状[J]. 国际医药卫生导报, 2022, 28(13): 1810-1814.
[13]	张泳欣, 肖学红, 唐秉航, 黎卫, 黄红星, 袁润强, 卢扬柏. PEComa临床病理分析与影像诊断[J]. 国际医药卫生导报, 2022, 28(10): 1372-1376.